Human papillomavirus (HPV) DNA replication is initiated by recruitment of the E1 helicase by the E2 protein to the viral origin. Screening of our corporate compound collection with an assay measuring the co-operative binding of E1 and E2 to the origin identified a class of small molecule inhibitors of the protein interaction between E1 and E2. Isothermal titration calorimetry and changes in protein fluorescence showed that the inhibitors bind to the transactivation domain (TAD) of E2, the region that interacts with E1. These compounds inhibit E2 of the low-risk HPV types 6 and 11, but not those of high-risk HPV types or of cottontail rabbit papillomavirus (CRPV). Functional evidence that the TAD is the target of inhibition was obtained by swapping this domain between a sensitive (HPV11) and a resistant (CRPV) E2 type and by identifying an amino acid substitution, E100A, that increases inhibition by approximately 10-fold. This class of inhibitors was found to specifically antagonize the E1-E2 interaction in vivo and to inhibit HPV DNA replication in transiently transfected cells. These results highlight the potential of the E1-E2 interaction as a small molecule antiviral target.
INTRODUCTION
Papillomaviruses are a family of small double-stranded DNA viruses that induce benign and malignant hyperproliferative lesions of the differentiating epithelium (reviewed in [1] [2] [3] [4] . Approximately 25 types of human papillomavirus 4 antivirals to treat HPV infections. In reality, however, not all targets are readily amenable to inhibition by small molecules. Protein interactions for example have been considered difficult to inhibit because they often involve large surfaces devoid of small molecule binding pockets (27, 28) . In absence of structural information, one often has to rely on screening large compound collections to determine if a protein can be antagonized by small molecules and for the identification of lead inhibitors.
Here we present a class of small molecules that bind reversibly to the E2 transactivation domain and inhibit the E1-E2 protein interaction in vitro and in vivo. The chemical features and synthetic procedures for these molecules will be described elsewhere 2 . To our knowledge these are the first small molecule inhibitors of HPV DNA replication with cellular activity. As such they highlight the potential of the E1-E2 interaction as an antiviral drug target.
EXPERIMENTAL PROCEDURES
Inhibitors. The syntheses of inhibitors 1 and 2 will be described (Clontech). HPV/CRPV E2 chimeras were constructed by PCR-mediated ligation as described previously (29) and cloned into pCR3.1. Site directed mutagenesis of E2 was performed with the QuickChange site-directed mutagenesis kit (Stratagene). For the plasmids described above, details of the construction and the sequence of the oligonucleotide primers used for PCR or mutagenesis will be made available upon request.
Proteins. His-E2 TAD from HPV11 was expressed from E. coli strain BL21(DE3) pLysS and purified by nickel affinity and size exclusion chromatography (Hi-trap and Superdex 75, Pharmacia) in a buffer composed of 6 25 mM Tris, 500 mM NaCl, and 5 mM TCEP (pH 8.0 at room temperature).
Yield was 11 mg per L of culture and His-TAD was essentially pure as judged by SDS-PAGE or analytical-scale size exclusion chromatography. Preparation of purified SV40 T antigen (30) , purified E1 and E1-containing nuclear extracts (31) , purified E2 (31) , and GST-E2 TAD (20) have been described previously. The TNT coupled reticulocyte lysate system (Promega) was used for in vitro translation of E1 and E2 as described (20) .
E1-E2-ori complex formation and related assays. E1-E2-ori complex
formation was monitored essentially as described previously (31) . Unless stated otherwise, all E1-E2-ori complex formation assays were performed with purified E2 and E1-containing nuclear extracts. E1-contaning nuclear extracts were titrated in the assay and used at a concentration yielding 70% of maximal activity.
Wells without E1 or E2 served as negative controls. In assays performed with in vitro translated E2, 2 µl of translation reaction was used per binding reaction. In this case, wells containing E2 but no E1 were used as negative controls, since 7 probe encompassing nucleotides 5191-31 of the SV40 genome. This probe was generated by PCR using pCH110 (Pharmacia), which contains the SV40 ori, and primers 5'-GCC CCT AAC TCC GCC CAT CCC GC-3' and 5'-ACC AGA CCG CCA CGG CTT ACG GC-3'. Detection was performed using the antibody PAb 101 (32) and protein A SPA beads.
For assays using in vitro translated CRPV E2 proteins or HPV11/CRPV E2 chimeras containing the CRPV DNA binding domain, a radiolabeled probe for the CRPV origin was used. A modified detection procedure was used for the experiment in Figure 6 to compensate for the weaker signal obtained in assays with proteins containing the CRPV DNA binding domain. After the 1 h binding reaction, the mixture was transferred to HVB filter plates (Whatman) to which an SPA bead-E1 antibody suspension had previously been added. After incubating the mixture for one hour with slight shaking, bead-bound protein-DNA complexes were washed by vacuum filtration, which removed the red-colored reticulocyte lysate that slightly quenches detection and also reduced background since unbound probe was washed away. Scintillation fluid was then added (Microscint 20 (Packard), 150 µl per well), the plates were shaken vigorously for several minutes, and counted using a Topcount NXT scintillation detector (Packard). inhibitors (if used) and 0.5 µl of E1-containing nuclear extract were added. Buffer for this step contained 6% DMSO. After 2 hours, bound E1 was detected by successive incubations with the same anti-E1 serum used in the E1-E2-DNA complex formation assay and then with HRP-linked Goat anti-rabbit antibody (Sigma). Antibody buffers were further supplemented with 0.5% BSA and 0.05% Tween-20. After washing, HRP activity was detected using o-phenylenediamine substrate (Sigma) according to the manufacturer's instructions.
Fluorescence quenching experiments. Fluorescence spectra were acquired using an SLM Aminco 8100 spectrometer with a neutral density filter in place and excitation and emission slits set to 4. Samples of proteins at 400 nM were excited at 280 nm and the emission intensity was recorded over the range from 300-380 nm. For each protein/inhibitor combination, spectra were acquired 9 from three individually prepared 0.5 ml samples. Signals from the three replicates were averaged, and for each wavelength, the displayed signal is the average from a 3 nm range.
Isothermal titration calorimetry. The calorimetry experiment was carried out using the VP-ITC microcalorimeter (Microcal Inc.) at a temperature of 25°C.
Purified His-tagged HPV11 TAD was exchanged into an aqueous buffer consisting of 20 mM Tris, 100 mM NaCl, and 0.5 mM TCEP, plus 2% DMSO. Reversibility of inhibition. Reversibility of inhibition was monitored using a modified version of the E1-E2-ori complex formation assay described above.
E2 (23 ng/µl) was mixed with inhibitor in assay buffer at a concentration equal to or greater than the IC 50 . The mixture was then diluted 19-fold and combined with E1 and radiolabeled probe such that the overall dilution of inhibitor was 32-fold.
Controls without inhibitor were run in parallel and used as the reference for calculation of inhibition. The final concentration of E2 was five-fold higher in preincubation assays (10 nM vs. 2 nM) to compensate for the significant decrease in signal observed on preincubation of E2.
Transient HPV DNA replication assay. Transient HPV DNA replication was performed as described previously (20, 33, 34 
RESULTS

Identification of a class of small molecules that inhibit the cooperative binding of HPV11 E1 and E2 to the origin. Co-operative binding of
E1 and E2 to the viral origin is an essential step in the initiation of HPV DNA replication. To identify inhibitors of this process, a high-throughput screening assay was developed that measures the binding of E1 and E2 to 33 P-radiolabeled origin DNA. Binding of E1 to the origin probe was detected by immuno-capture of E1-DNA complexes using an anti-E1 antibody coupled to scintillation proximity assay (SPA, 34) beads ( Figure 1A ). Binding reactions were performed in the presence of an excess of unlabeled non-specific competitor DNA to ensure that binding of E1 to the origin probe was dependent on its association with E2. Figure 1B shows that a strong signal was detected only when E1 and E2 were added to the reaction. This signal was dependent on the association of E1 with E2 since it was reduced to background levels by the E39A amino acid substitution in E2 that abrogates E1 binding (36) (37) (38) . In contrast the I73A substitution, which affects primarily the transactivation function of E2 and not its ability to bind to E1 (37, 38) , had little effect.
Screening of our corporate compound collection with this assay yielded inhibitor 1 shown in Figure 2 . Modification of this inhibitor led to more potent compounds 2 such as 2 and 3 ( Figure 2 ). These three compounds were inactive or only weakly active in a mechanistically related SPA that measures binding of These results suggested that the E1-E2 protein interaction might be the target of
inhibition. This hypothesis was tested using an ELISA. The E2 protein used in this assay was either purified from baculovirus-infected insect cells or obtained by in vitro translation; both sources yielding similar results. Binding of 13 recombinant E1 to immobilized E2 was detected using an anti-E1 antiserum followed by a secondary antibody coupled to horseradish peroxidase. As seen in Figure 3A , the signal was dependent on the interaction of E1 with E2 since it was reduced by the E39A substitution in E2. As anticipated, the I73A substitution had little effect. As can be seen in Figures Functional evidence that the E2 TAD is the target of inhibition. During the course of this study we found that in vitro translated CRPV E2 can bind cooperatively with purified HPV11 E1 to either the HPV11 or CRPV origins, albeit weakly. CRPV E2, however, was found to be resistant to inhibition by compound 2 ( Figure 6 ), perhaps not surprisingly given the low level of amino acid identity between the TAD of HPV11 and that of CRPV. Similarly, we found that the inhibitors are inactive against the E2 protein of the high-risk HPV types 16, 18 and 31 (data not shown), which at the amino acid level are only 41-50% identical to HPV11 E2. We made use of the observation that some E2 types are resistant to inhibition to substantiate the finding that the TAD is indeed the target of the inhibitors. Specifically, we constructed chimeric E2 proteins encoding the HPV11 TAD with the hinge and DNA-binding domain from CRPV, or the opposite combination. These chimeras were expressed in vitro and tested in the E1-E2-ori complex formation assay using HPV11 E1. Both chimeras could bind cooperatively with E1 on the origin, but only the one containing the TAD from HPV11 was sensitive to inhibition by compound 2 ( Figure 6 ). This result provides functional evidence that the TAD is indeed the target of inhibition.
Inhibition is reversible.
It is generally expected to be difficult to identify inhibitors of protein interactions that act by reversible binding rather than by reacting with the target protein or by some other irreversible mechanism (27) . To determine if inhibition of E1-E2-ori complex formation was reversible, we performed the pre-incubation experiment shown in Figure 7 . In this experiment, E2, the target protein, was incubated with a high concentration of inhibitor and then diluted into the E1-E2-ori complex formation assay to a final compound concentration ten-fold below the IC 50 . We reasoned that if the inhibitor is acting by a reversible mechanism, the activity of E2 should be recovered upon dilution of the inhibitor. However, if the mechanism of inhibition is irreversible then significant inhibition should be observed even after dilution. As a control, we used which affects E1-binding ( Figure 9B ). As expected, the I73A substitution in E2 had no negative effect.
Having confirmed that expression of the reporter gene was dependent on the interaction between E1 and E2, we then tested the effect of compounds 2 and 3 in this assay and in a similar one based on E1 and E2 from HPV6. but could be related to slight alterations in the conformation of E2 in vivo compared to in vitro (see Discussion). As a control for specificity, we verified that the inhibitors had little effect on the expression of an unrelated SEAP reporter transactivated by a GAL4-VP16 fusion protein ( Figure 10 ). As an additional control for specificity, we showed that an enantiomer of inhibitor 3 that is nearly inactive in vitro (IC 50 =29 µM in the E1-E2-ori complex formation assay) was also inactive in the cellular assay (data not shown).
To gain additional evidence that the inhibitors were acting in vivo by the same mechanism as in vitro we made use of a mutant E2 protein that has a higher affinity for this class of inhibitors. This mutant protein contains a single amino substitution in the TAD, E100A, which makes it approximately 10 fold more sensitive to this class of inhibitors than wild type E2, in the in vitro E1-E2-ori complex formation assay. The E100A substitution was discovered during a mutational analysis of the E2 TAD aimed at identifying residues involved in compound binding (to be published elsewhere). Importantly, this amino acid substitution also increased the sensitivity of E2 in the reporter assay ( Figure 10 ).
This result provides strong evidence that the mechanism of action of this class of inhibitors is the same in vivo as in vitro. 
DISCUSSION
Discovery of inhibitors of the E1-E2 interaction. In this manuscript
Amino acids in E2 involved in inhibition.
Prior to this report a 15 amino acid peptide derived from HPV16 E2 and spanning residue E39 was shown to be capable of inhibiting the E1-E2 interaction in vitro (45). Several studies have suggested an essential role for E39 in interaction with E1. Specifically, changing this residue to alanine was shown to abrogate the ability of E2 to bind to E1 (36) (37) (38) , as confirmed in this study, while having little effect on its transcriptional activity. These findings suggested that E39 might form part of the E1-binding surface on E2. Two lines of evidence suggest that our inhibitors may bind near E39 to antagonize the E1-E2 interaction. Firstly, the E100 residue, which when changed to alanine increases the sensitivity of HPV11 E2 to our inhibitors, is located on the same surface as E39 in the crystal structure of the HPV16 E2 TAD (46). Secondly, we found that our inhibitors bind with reduced affinity to the E39A mutant E2 TAD in fluorescence studies similar to those presented in Figure   4 (data not shown). The simplest interpretation of these results is that the surface of the E2 TAD onto which E39 and E100 are located is involved in binding both E1 and our inhibitors. Because these inhibitors are inactive against HPV16 E2
we did not attempt to model them into the published structure of the HPV16 E2 TAD. However, further studies are in progress to localize the inhibitor-binding pocket on the HPV11 E2 TAD. 
Protein interactions as drug targets.
